Aspira Pathlab (540788)
Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹31 |
| Market Cap | ₹31.96 Cr |
| P/E Ratio | 39.91 |
| ROCE | 17.37% |
| ROE | 13.19% |
| Dividend Yield | 0% |
| Profit Growth | -510.53% |
| Debt/Equity | — |
| Sales Growth | -5.36% |
| 52-Week Range | ₹49 — ₹119 |
| Sector | Healthcare Services |
| Book Value | ₹9.84 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At first glance, Aspira Pathlab sits in an industry I respect—healthcare services—but that alone does not justify investment. At ₹31, the market cap is just ₹32 crore. The latest quarter tells an alarming story: revenue of ₹5 crore and a net loss of ₹2 crore, implying a 40% net loss margin. Sales have declined 5.36% and profit growth has collapsed by 510.53%. This is not the earning power I look for.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer